{
    "paper_id": "323d3b8624f452295f0627cd49668040e5f1c3f1",
    "metadata": {
        "title": "The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection",
        "authors": [
            {
                "first": "Brandon",
                "middle": [],
                "last": "Beddingfield",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Tulane National Primate Research Center",
                    "location": {
                        "addrLine": "18703 Three Rivers Road",
                        "postCode": "70433",
                        "settlement": "Covington",
                        "region": "LA",
                        "country": "U.S.A"
                    }
                },
                "email": ""
            },
            {
                "first": "Naoki",
                "middle": [],
                "last": "Iwanaga",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Tulane University School of Medicine",
                    "location": {
                        "postCode": "70112",
                        "settlement": "New Orleans",
                        "region": "LA",
                        "country": "U.S.A"
                    }
                },
                "email": ""
            },
            {
                "first": "Prem",
                "middle": [],
                "last": "Chapagain",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Florida International University",
                    "location": {
                        "postCode": "33199",
                        "settlement": "Miami",
                        "region": "FL",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Wenshu",
                "middle": [],
                "last": "Zheng",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Tulane University School of Medicine",
                    "location": {
                        "postCode": "70112",
                        "settlement": "New Orleans",
                        "region": "LA",
                        "country": "U.S.A"
                    }
                },
                "email": ""
            },
            {
                "first": "Chad",
                "middle": [
                    "J"
                ],
                "last": "Roy",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Tulane National Primate Research Center",
                    "location": {
                        "addrLine": "18703 Three Rivers Road",
                        "postCode": "70433",
                        "settlement": "Covington",
                        "region": "LA",
                        "country": "U.S.A"
                    }
                },
                "email": ""
            },
            {
                "first": "Tony",
                "middle": [
                    "Y"
                ],
                "last": "Hu",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Tulane University School of Medicine",
                    "location": {
                        "postCode": "70112",
                        "settlement": "New Orleans",
                        "region": "LA",
                        "country": "U.S.A"
                    }
                },
                "email": ""
            },
            {
                "first": "Jay",
                "middle": [],
                "last": "Kolls",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Tulane University School of Medicine",
                    "location": {
                        "postCode": "70112",
                        "settlement": "New Orleans",
                        "region": "LA",
                        "country": "U.S.A"
                    }
                },
                "email": ""
            },
            {
                "first": "Gregory",
                "middle": [],
                "last": "Bix",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Tulane University School of Medicine",
                    "location": {
                        "postCode": "70112",
                        "settlement": "New Orleans",
                        "region": "LA",
                        "country": "U.S.A"
                    }
                },
                "email": "gbix@tulane.edu"
            },
            {
                "first": "F",
                "middle": [
                    "A H A"
                ],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "inhibiting SARS-CoV-2 entry through a hypothesized \u03b1 5\u03b21 integrin-based mechanism, and indicates that inhibiting the spike protein interaction with \u03b1 5\u03b21 integrin (+/-ACE2), and the interaction between \u03b1 5\u03b21 integrin and ACE2 using a molecule ATN-161 represents a promising approach to treat COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "protein-protein docking using Zdock with the ACE2 residues around KGD and the \u03b1 5\u03b21 residues around the RGD-binding site selected as preferred binding partners. This docking results in a complex with the desired orientations of the integrin chains (27) and ACE2 relative to the plasma membrane ( Fig 1A) . As shown in Fig. 1B , the binding of the \u03b1 5\u03b21 to ACE2 at this site masks the binding site for the spike RDB, potentially inhibiting the SARS-CoV-2 entry (26) . The binding of ATN-161 in the interface may disrupt the \u03b1 5\u03b21-ACE2 complex. Separately, we performed docking of \u03b1 5\u03b21 to the spike protein RBD, which contains the RGD sequence that is accessible for binding. This results in a complex of the spike RBD and \u03b1 5\u03b21 as shown in Fig. 1C . For this binding to occur, the RGD-binding interface of integrin needs to be oriented differently than binding with ACE2, consistent with the active conformation of integrin (7) . ATN-161 binding near the RGD motif binding site of integrin may inhibit the \u03b1 5\u03b21spike RBD complex formation. We hypothesize that SARS-CoV-2 entry is facilitated by binding to ACE2-associated \u03b1 5\u03b21 integrin via its spike protein, and that ATN-161 treatment will inhibit infection by blocking this binding event and by disrupting the initial ACE2 and \u03b1 5\u03b21 interaction ( Figure 1D ).",
            "cite_spans": [
                {
                    "start": 248,
                    "end": 252,
                    "text": "(27)",
                    "ref_id": "BIBREF23"
                },
                {
                    "start": 460,
                    "end": 464,
                    "text": "(26)",
                    "ref_id": "BIBREF22"
                },
                {
                    "start": 924,
                    "end": 927,
                    "text": "(7)",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [
                {
                    "start": 296,
                    "end": 303,
                    "text": "Fig 1A)",
                    "ref_id": "FIGREF4"
                },
                {
                    "start": 318,
                    "end": 325,
                    "text": "Fig. 1B",
                    "ref_id": "FIGREF4"
                },
                {
                    "start": 740,
                    "end": 747,
                    "text": "Fig. 1C",
                    "ref_id": "FIGREF4"
                },
                {
                    "start": 1300,
                    "end": 1309,
                    "text": "Figure 1D",
                    "ref_id": "FIGREF4"
                }
            ],
            "section": ""
        },
        {
            "text": "In this study, we explored the binding of the SARS-CoV-2 spike protein with ACE2 and \u03b1 5\u03b21, utilizing ELISA-based methods. To determine the spike protein's ability to bind \u03b1 5\u03b21, plates were coated with \u03b1 5\u03b21 and incubated with a mixture of ATN-161 and a trimeric version of the spike protein. The SARS-CoV-2 spike protein binds to \u03b1 5\u03b21 with an affinity that is roughly equivalent to \u03b1 5\u03b21's native ligand, fibronectin (28) , and inhibits binding with a U-shaped (Donate et al., 2008) dose-dependent manner, with maximum effect at 100nM (Figure 2A ). To our knowledge, this is the first report of SARS-CoV-2 spike protein interaction with integrins, and specifically \u03b1 5\u03b21. We performed similar assays to investigate ACE2 binding to \u03b1 5\u03b21, using a mixture of ATN-161 and human ACE2 protein (hACE2). Clear inhibition of ACE2/\u03b15\u03b21 binding by ATN-161 was apparent and dose-dependent ( Figure 2B ). Furthermore, application of ATN-161 reduced binding of trimeric spike protein to hACE2, either alone or in combination with \u03b1 5\u03b21, the latter of which trended to support greater spike binding than to hACE2 alone ( Figure 2C ). Application of ATN-161 also reduced binding of monomeric spike to hACE2 ( Figure S1 ).",
            "cite_spans": [
                {
                    "start": 420,
                    "end": 424,
                    "text": "(28)",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 464,
                    "end": 485,
                    "text": "(Donate et al., 2008)",
                    "ref_id": "BIBREF17"
                }
            ],
            "ref_spans": [
                {
                    "start": 538,
                    "end": 548,
                    "text": "(Figure 2A",
                    "ref_id": "FIGREF5"
                },
                {
                    "start": 883,
                    "end": 892,
                    "text": "Figure 2B",
                    "ref_id": "FIGREF5"
                },
                {
                    "start": 1110,
                    "end": 1119,
                    "text": "Figure 2C",
                    "ref_id": "FIGREF5"
                },
                {
                    "start": 1197,
                    "end": 1206,
                    "text": "Figure S1",
                    "ref_id": "FIGREF4"
                }
            ],
            "section": ""
        },
        {
            "text": "The in vitro assessment of ATN-161 and therapeutic potential was performed using a once-passaged Vero (E6) African green monkey (Chlorocebus atheiops) kidney cell line utilizing competent SARS-CoV-2. ATN-161 was effective at reducing viral loads after infection ( Figure 3A) , with an estimated IC 50 of 3.16 \u00b5M. The EC 50 value for ATN-161 approximates the value for remdesivir (8) . Importantly, Vero (E6) have been previously shown to express \u03b1 5\u03b21 integrin (29) .",
            "cite_spans": [
                {
                    "start": 379,
                    "end": 382,
                    "text": "(8)",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 461,
                    "end": 465,
                    "text": "(29)",
                    "ref_id": "BIBREF25"
                }
            ],
            "ref_spans": [
                {
                    "start": 264,
                    "end": 274,
                    "text": "Figure 3A)",
                    "ref_id": "FIGREF6"
                }
            ],
            "section": ""
        },
        {
            "text": "Measuring cellular viability and underlying cytotoxicity is another metric for antiviral therapeutic potential that we explored with ATN-161 (30) . After 24 hours infection at a MOI of 0.01, cells were lysed with CellTiterGlo and luminescence values were taken to measure ATP production in each treatment. Pretreatment with ATN-161 increased ATP production in infected cells, indicating increased viability, and was consistent with viral PCR data at concentrations as low as 1\u00b5M ATN-161 ( Figure 3B ). Addition of 10 \u00b5M ATN-161 resulted in a decreased cytopathic effect (i.e. fewer apparent rounded, bright cells) when cells were visualized by phase contrast microscopy ( Figure 3C ).",
            "cite_spans": [
                {
                    "start": 141,
                    "end": 145,
                    "text": "(30)",
                    "ref_id": "BIBREF26"
                }
            ],
            "ref_spans": [
                {
                    "start": 489,
                    "end": 498,
                    "text": "Figure 3B",
                    "ref_id": "FIGREF6"
                },
                {
                    "start": 672,
                    "end": 681,
                    "text": "Figure 3C",
                    "ref_id": "FIGREF6"
                }
            ],
            "section": ""
        },
        {
            "text": "In summary, we show that SARS-CoV-2 spike protein binds to both \u03b1 5\u03b21 and \u03b1 5\u03b21/hACE2, and that this binding can be effectively inhibited by ATN-161, which also disrupts SARS-CoV-2 infection in vitro. Prophylactic treatment of ATN-161 increased cell viability in the presence of SARS-CoV-2 and decreased cytopathic effects associated with viral infection. Taken together, and in light of ATN-161's previously demonstrated in vivo therapeutic efficacy against a closely related beta-coronavirus (porcine hemagglutinating encephalomyelitis virus (23) ) and its successful use in human cancer clinical trials (31) , these results support the performance of in vivo studies to assess the potential efficacy of ATN-161 as an experimental therapeutic agent for COVID-19.",
            "cite_spans": [
                {
                    "start": 544,
                    "end": 548,
                    "text": "(23)",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 606,
                    "end": 610,
                    "text": "(31)",
                    "ref_id": "BIBREF27"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "VeroE6 cells (ATCC# CRL-1586) were cultured in complete DMEM containing 10% fetal bovine serum (FBS). SARS-CoV-2 stock from viral seed (SARS-CoV-2; 2019-nCoV/USA-WA1/2020 (BEI# NR-52281) was obtained by infecting nearly confluent monolayers of VeroE6 cells for one hour with a minimal amount of liquid in serum free DMEM. Once adsorption was complete, complete DMEM containing 2% FBS was added to the cells and the virus was allowed to propagate at 37 in 5% CO 2 . Upon the presence of CPE in the majority of the monolayer, the virus was harvested by clearing the supernatant at 1,000 xg for 15 minutes, aliquoting and freezing at -80 . Sequencing confirmed consensus sequence was unchanged from the original isolate.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cells and Virus"
        },
        {
            "text": "Enzyme-Linked Immunosorbent Assay (ELISA) was utilized to determine the ability of ATN-161 to disrupt binding events essential to entry of SARS-CoV-2 into a host cell. For determination of inhibition of ACE2/ \u03b1 5\u03b21 integrin binding by ATN-161, \u03b1 5\u03b21 was coated on 96-well plates at 1 \u00b5g/mL for 2 hours at room temperature and blocked overnight with 2.5% BSA. Addition of 0.5 \u00b5g/mL of hACE2-Fc (Sino Biological, Cat# 10108-H02H) in differing concentrations of ATN-161 followed, incubating for 1 hour at 37 . Incubation with an HRP labeled goat anti-human Fc secondary antibody at 1:5000 for 30 minutes at 37 was followed by detection by TMB substrate.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "ELISA Analysis of ATN-161 Inhibition of SARS-CoV-2 Spike Protein Binding to ACE2 and Integrin"
        },
        {
            "text": "In order to assess disruption of binding of \u03b1 5\u03b21 to SARS-CoV-2 Spike protein, 96-well plates were coated as before, but incubation with ATN-161 was performed in conjunction with 1\u00b5g/mL spike (produced under HHSN272201400008C and obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2, Wuhan-Hu-1, Recombinant from HEK293 Cells, NR-52306) in the presence of 1mM MnCl 2 , followed by detection with an anti-spike antibody. The rest of the procedure was consistent with the previous.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "ELISA Analysis of ATN-161 Inhibition of SARS-CoV-2 Spike Protein Binding to ACE2 and Integrin"
        },
        {
            "text": "In order to determine the ability of ATN-161 to reduce the infection capability of SARS-CoV-2 in vitro, a cell-based assay was utilized. VeroE6 cells were plated at a density of 1.25 x 10 4 cells/well in a 96-well plate and incubated overnight at 37 in 5% CO 2 . The next day, cells were treated with dilutions of ATN-161 in complete DMEM with 2% FBS for one hour at 37 in 5% CO 2 , followed by viral infection at an MOI of 0.1. After 48 hours, virus and cells were lysed via Trizol LS and RNA was extracted using a Zymo Direct-zol 96 RNA Kit (#R2056) according to manufacturer's instructions. Experiments were performed under Biosafety Level 3 conditions in accordance with institutional guidelines.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "In vitro assessment of ATN-161 Inhibition of SARS-CoV-2 Infection"
        },
        {
            "text": "Viral load was quantified using a Reverse Transcriptase qPCR targeting the SARS-CoV-2 nucleocapsid gene. RNA isolated from cell cultures was plated in duplicate and analyzed in an Applied Biosystems 7300 using TaqPath supermix with the following program: i)50 for 15 min., ii) 95 for 2 min. and iii) 45 cycles of 95 for 3s and 55 for 30s. The primers and probes were as follows: 2019-nCoV_N1 Forward ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "RT-qPCR"
        },
        {
            "text": "The day before infection, Nunc LabTek II chamber slides (Thermo, USA) were seeded with 2.5 x 10 4 cells per chamber. On the day of infection, chambers were treated with dilutions of ATN-161 in complete DMEM with 2% FBS for one hour prior to infecting with SARS-CoV-2 at an MOI of 0.01. Slides were placed in a 37 5% CO 2 incubator for 24 hours prior to imaging via phase contrast using an EVOS XL inverted microscope (Thermo, USA).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cell Imaging"
        },
        {
            "text": "Ability of ATN-161 to increase cell viability was performed with CellTiterGlo (Promega, USA). Cell supernatant was removed 24 hours post infection and cells were lysed via pre-mixed CellTiterGlo reagent. Cells were incubated for 15 minutes and allowed to shake briefly before ATP was quantified via luminescence readout on the GloMax Explorer multimode plate reader (Promega).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cell Viability Assay"
        },
        {
            "text": "The structure of the ACE2-Spike protein receptor binding domain complex (7) was obtained from the protein data bank (PDB ID 6m0j). To get the orientation of the SARS-CoV-2 spike protein trimer relative to ACE2, the receptor binding domain (RBD) was aligned with the sprung out RBD of the prefusion conformation of the spike protein trimer (PDB ID 6vsb) (32) . Similarly, the integrin \u03b1 5\u03b21 ectodomain structure (25) was obtained from the protein data bank (PDB ID 3vi3), with the calf1 and calf2 domains of \u03b1 5 added from the PDB ID 6naj (33). ATN-161 (Ac-PHSCN-NH2) was prepared for docking with Autodock vina (34). ATN-161 was docked \u03b1 5\u03b21 complex, ACE2, and ACE2-spike RBD complex. ZDock 3.0.2 (35) server was used for protein-protein docking to generate the \u03b1 5\u03b21 complexed with ACE2 as well as with the spike RBD. The structures were rendered using PyMol 2.3.0 (36).",
            "cite_spans": [
                {
                    "start": 353,
                    "end": 357,
                    "text": "(32)",
                    "ref_id": null
                },
                {
                    "start": 411,
                    "end": 415,
                    "text": "(25)",
                    "ref_id": "BIBREF21"
                }
            ],
            "ref_spans": [],
            "section": "Molecular Modeling"
        },
        {
            "text": "Differences between groups was determined via the one-way ANOVA using Dunnett's multiple comparisons test. Experiments are represented as weighted mean and standard deviation of a total of three replicates. For IC 50 estimation, the data points directly bounding the IC 50 value were used and calculation was made in GraphPad Prism. Viral load studies were performed 3 separate times with each condition done in triplicate in each experiment. All ELISA studies were performed two times with each condition done in triplicate. The cell viability assay was performed a single time, each condition in triplicate. Inhibition of SARS-CoV-2 spike protein binding to human ACE2 by ATN-161. Plates were precoated with monomeric spike protein and incubated with a mixture of hACE2 and various ATN-161 concentrations, followed by detection of bound hACE2 via HRP-conjugated anti-ACE2 antibody. Data was normalized to a no-ATN vehicle control. Data represent mean \u00b1 SD, n=3, * P<0.05, ** P<0.01. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statistics"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Coronavirus disease (COVID-19) pandemic. World Heal Organ",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "The proximal origin of SARS-CoV-2",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "G"
                    ],
                    "last": "Andersen",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Rambaut",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "I"
                    ],
                    "last": "Lipkin",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "C"
                    ],
                    "last": "Holmes",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "F"
                    ],
                    "last": "Garry",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nat Med",
            "volume": "26",
            "issn": "",
            "pages": "450--452",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence",
            "authors": [
                {
                    "first": "V",
                    "middle": [
                        "D"
                    ],
                    "last": "Menachery",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "L"
                    ],
                    "last": "Yount",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Debbink",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Agnihothram",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "E"
                    ],
                    "last": "Gralinski",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Plante",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "L"
                    ],
                    "last": "Graham",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Scobey",
                    "suffix": ""
                },
                {
                    "first": "X-Y",
                    "middle": [],
                    "last": "Ge",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "F"
                    ],
                    "last": "Donaldson",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "H"
                    ],
                    "last": "Randell",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Lanzavecchia",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "A"
                    ],
                    "last": "Marasco",
                    "suffix": ""
                },
                {
                    "first": "Z-L",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "S"
                    ],
                    "last": "Baric",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Nat Med",
            "volume": "21",
            "issn": "",
            "pages": "1508--1513",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Lan",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Ge",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Shan",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Fan",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature",
            "volume": "581",
            "issn": "",
            "pages": "215--220",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Zhong",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Xiao",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Res",
            "volume": "30",
            "issn": "",
            "pages": "269--271",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Caly",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Druce",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "G"
                    ],
                    "last": "Catton",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "A"
                    ],
                    "last": "Jans",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "M"
                    ],
                    "last": "Wagstaff",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Antiviral Res",
            "volume": "178",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Xia",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Lan",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Feng",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Qi",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Bao",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Qin",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Res",
            "volume": "30",
            "issn": "",
            "pages": "343--355",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "A human monoclonal antibody blocking SARS-CoV-2 infection",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Drabek",
                    "suffix": ""
                },
                {
                    "first": "Nma",
                    "middle": [],
                    "last": "Okba",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Van Haperen",
                    "suffix": ""
                },
                {
                    "first": "Adme",
                    "middle": [],
                    "last": "Osterhaus",
                    "suffix": ""
                },
                {
                    "first": "Fjm",
                    "middle": [],
                    "last": "Van Kuppeveld",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "L"
                    ],
                    "last": "Haagmans",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Grosveld",
                    "suffix": ""
                },
                {
                    "first": "B-J",
                    "middle": [],
                    "last": "Bosch",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nat Commun",
            "volume": "11",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "A potential role for integrins in host cell entry by SARS-CoV-2",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Sigrist",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Bridge",
                    "suffix": ""
                },
                {
                    "first": "Le",
                    "middle": [],
                    "last": "Mercier",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Antiviral Res",
            "volume": "177",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Proc Natl Acad Sci",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "New Strategy for COVID-19: An Evolutionary Role for RGD Motif in SARS-CoV-2 and Potential Inhibitors for Virus Infection",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Yan",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Bu",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Wan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Front Pharmacol",
            "volume": "11",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "SARS-COV-2 and infectivity: Possible increase in infectivity associated to integrin motif expression",
            "authors": [
                {
                    "first": "I",
                    "middle": [],
                    "last": "Tresoldi",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "F"
                    ],
                    "last": "Sangiuolo",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Manzari",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Modesti",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Med Virol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Angiotensin Converting Enzyme (ACE) and ACE2 Bind Integrins and ACE2 Regulates Integrin Signalling",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "E"
                    ],
                    "last": "Clarke",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Fisher",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "E"
                    ],
                    "last": "Porter",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "W"
                    ],
                    "last": "Lambert",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Turner",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "PLoS One",
            "volume": "7",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Interaction of ACE2 and integrin \u03b2 1 in failing human heart",
            "authors": [
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "S"
                    ],
                    "last": "Keller",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Weaver",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "S"
                    ],
                    "last": "Zisman",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Biochim Biophys Acta -Mol Basis Dis",
            "volume": "1689",
            "issn": "",
            "pages": "175--178",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Donate",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "C"
                    ],
                    "last": "Parry",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Shaked",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Hensley",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Beck",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Tel-Tsur",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Plunkett",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Manuia",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "E"
                    ],
                    "last": "Shaw",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "S"
                    ],
                    "last": "Kerbel",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "P"
                    ],
                    "last": "Mazar",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Clin Cancer Res",
            "volume": "14",
            "issn": "",
            "pages": "2137--2144",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Integrin \u03b1 5\u03b21 inhibition by ATN-161 reduces neuroinflammation and is neuroprotective in ischemic stroke",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "N"
                    ],
                    "last": "Edwards",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Salmeron",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "E"
                    ],
                    "last": "Lukins",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "L"
                    ],
                    "last": "Trout",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "F"
                    ],
                    "last": "Fraser",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "J"
                    ],
                    "last": "Bix",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "J Cereb Blood Flow Metab",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "ATN-161 reduces virus proliferation in PHEV-infected mice by inhibiting the integrin \u03b1 5\u03b21-FAK signaling pathway",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Lv",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Lan",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Vet Microbiol",
            "volume": "233",
            "issn": "",
            "pages": "147--153",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Khalili",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Mol Cancer Ther",
            "volume": "5",
            "issn": "",
            "pages": "2271--2280",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Crystal structure of \u03b1 5\u03b21 integrin ectodomain: Atomic details of the fibronectin receptor",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Nagae",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Re",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Mihara",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Nogi",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Sugita",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Takagi",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "J Cell Biol",
            "volume": "197",
            "issn": "",
            "pages": "131--140",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "A potential inhibitory role for integrin in the receptor targeting of SARS-CoV-2",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Luan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Infect",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Structure and mechanics of integrin-based cell adhesion",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Arnaout",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "L"
                    ],
                    "last": "Goodman",
                    "suffix": ""
                },
                {
                    "first": "J-P",
                    "middle": [],
                    "last": "Xiong",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Curr Opin Cell Biol",
            "volume": "19",
            "issn": "",
            "pages": "495--507",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "The Short Amino Acid Sequence Pro-His-Ser-Arg-Asn in Human Fibronectin Enhances Cell-Adhesive Function",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Aota",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Nomizu",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "M"
                    ],
                    "last": "Yamada",
                    "suffix": ""
                }
            ],
            "year": 1994,
            "venue": "J Biol Chem",
            "volume": "269",
            "issn": "",
            "pages": "24756--61",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Proteomic Analysis of Membrane Proteins of Vero Cells: Exploration of Potential Proteins Responsible for Virus Entry",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Guo",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "DNA Cell Biol",
            "volume": "33",
            "issn": "",
            "pages": "20--28",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Hoffmann",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Kleine-Weber",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Schroeder",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Kr\u00fcger",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Herrler",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Erichsen",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "S"
                    ],
                    "last": "Schiergens",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Herrler",
                    "suffix": ""
                },
                {
                    "first": "N-H",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Nitsche",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "M\u00fcller",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Drosten",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "P\u00f6hlmann",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell",
            "volume": "181",
            "issn": "",
            "pages": "271--280",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "E"
                    ],
                    "last": "Cianfrocca",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "A"
                    ],
                    "last": "Kimmel",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Gallo",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Cardoso",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "M"
                    ],
                    "last": "Brown",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Hudes",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Lewis",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Weiner",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "N"
                    ],
                    "last": "Lam",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "C"
                    ],
                    "last": "Brown",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "E"
                    ],
                    "last": "Shaw",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "P"
                    ],
                    "last": "Mazar",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "B"
                    ],
                    "last": "Cohen",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Br J Cancer",
            "volume": "94",
            "issn": "",
            "pages": "1621--1626",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": ":5'-GAC CCC AAA ATC AGC GAA AT-3', 2019-nCoV_N1 Reverse: 5'-TCT GGT TAC TGC CAG TTG AAT CTG-3', and 2019-nCoV_N1 Probe: 5'-FAM-ACC CCG CAT TAC GTT TGG TGG ACC-BHQ1-3'. Standard curves were generated for each run using a plasmid containing SARS-CoV-2 nucleocapsid gene (Integrated DNA Technologies, USA).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Aguirre C, Meca-Lallana V, Barrios-Blandino A, del R\u00edo B, Vivancos J. 2020. Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role? Mult Scler Relat Disord 44:102250. 17. Ishibashi Y, Relman DA, Nishikawa A. 2001. Invasion of human respiratory epithelial cells by Bordetella pertussis: Possible role for a filamentous hemagglutinin Arg-Gly-Asp sequence and \u03b1 5\u03b21 integrin. Microb Pathog 30:279-288. 18. Napione L, Cascone I, Mitola S, Serini G, Bussolino F. 2007. Integrins: A flexible platform for endothelial vascular tyrosine kinase receptors. Autoimmun Rev 7:18-22. McLellan JS. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. MA. 2020. Structure-guided design of pure orthosteric inhibitors of \u03b1 IIb\u03b23 that prevent thrombosis but preserve hemostasis. Nat Commun 11:398. 34. Trott O, Olson AJ. 2009. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem NA-NA. 35. Pierce BG, Wiehe K, Hwang H, Kim B-H, Vreven T, Weng Z. 2014. ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers. Bioinformatics 30:1771-1773. 36. Schr\u00f6dinger L. 2015. The PyMOL Molecular Graphics System. 2.3.0.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "AUTHOR CONTRIBUTIONS G.B. conceived the study. B.B. conducted all live SARS-CoV-2 studies. N.I. and W.Z. conducted all ELISA's. B.B., N.I. and W.Z. collected data and performed computational analysis. P.C. performed 3D modeling analysis. B.B., C.R., T.H., J.K. and G.B. interpreted data and wrote the manuscript with input from all of the authors.DECLARATION OF INTERESTSG.B. is the inventor on a filed provisional patent with the USPTO related to this work. The remaining authors declare no competing interests.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "Figure legends",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "Molecular Model of ATN-161 Interactions with \u03b1 5\u03b21. (A) SARS-CoV-2 spike protein trimer bound to ACE2 via the sprung out spike protein receptor binding domain (RBD). Molecular docking of ATN-161 shows three potential binding sites (van der Waals representation in blue). (B) ACE2-alpha5beta1complex, with the KGD sequence is highlighted. The location of ATN-161 in site 2 is highlighted (blue surface representation) but was not included for protein-protein docking. (C) The Spike RBD-alpha5beta1 complex, with RGD sequence of the spike RBD highlighted. All conformations have the same orientation relative to the membrane in A. (D) Proposed mechanism of ATN-161 inhibition of SARS-CoV-2 infection, where addition of ATN-161 is proposed to inhibit SARS-CoV-2 spike protein binding to host \u03b1 5\u03b21 integrin, ACE2, as well as \u03b1 5\u03b21-ACE2 binding.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "ATN-161 effects on SARS-CoV-2 spike, ACE2 and \u03b1 5\u03b21 binding. ELISA data indicates that ATN-161 alters (A), binding of \u03b1 5\u03b21 to spike protein-coated plates, when these plates are incubated with \u03b1 5\u03b21 and concentrations of ATN-161 and (B) when \u03b1 5\u03b21coated plates are incubated with human ACE2 and concentrations of ATN-161, and (C) spike binding to ACE2 or ACE2 + \u03b1 5\u03b21 protein-coated plates. Data was normalized to no-ATN vehicle control (ACE2 Veh for D, stats as compared to respective Veh). Data represent mean \u00b1 SD, n=3, * P<0.05, ** P<0.01, *** P<0.001",
            "latex": null,
            "type": "figure"
        },
        "FIGREF6": {
            "text": "ATN-161 effects on SARS-CoV-2 infection in vitro. (A) Viral Load of SARS-CoV-2 with and without ATN-161 treatment. VeroE6 cells were incubated with indicated ATN-161 concentrations for one hour prior to 48 hours infection with SARS-CoV-2 at a MOI of 0.1. (B) Cell viability via luminescence-based CellTiterGlo 24 hours post-infection. (C) Representative phase contrast microscope images of VeroE6 cells 24 hours post-infection with and without 10 \u00b5M ATN-161 treatment. Black arrows indicate some of the visible viral cytopathic effect (rounded, phase bright cells). Scale bar is 10 \u00b5M. Data represent mean \u00b1 SD, n=3, * P<0.05, ** P<0.01, *** P<0.001",
            "latex": null,
            "type": "figure"
        },
        "FIGREF7": {
            "text": "Fig. S1",
            "latex": null,
            "type": "figure"
        },
        "FIGREF8": {
            "text": "Figure 2",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "We thank R Garry, Tulane University School of Medicine, for use of PCR reagents, N Maness at Tulane National Primate Research Center for viral stock, A Mazar, Monopar Therapeutics, for helpful discussions on the preparation and handling of ATN-161 for in vitro studies, I Rutkai and A Narayanappa for collection of technical information regarding antibodies used in ELISA studies, and S Yadav for advice on 3D modeling. We would also like to thank K Andersen at",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": " Figure 1 D.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 1,
                    "end": 9,
                    "text": "Figure 1",
                    "ref_id": null
                }
            ],
            "section": "annex"
        }
    ]
}